2022-11-04 11:13
Infant Bacterial Therapeutics AB (publ) announces the appointment of the Nomination Committee for the Annual General Meeting 2023
The 2022 Annual General Meeting resolved that the Chairman of the Board shall convene the three largest shareholders in the company in terms of voting...
The two independent primary endpoints of the ‘Connection Study’ are the incidence of NEC and the time to SFT. SFT a composite endpoint defined...
2022-09-23 08:00
FDA approves Infant Bacterial Therapeutics' request for a new orphan drug designation
Building upon Infant Bacterial Therapeutics AB’s (IBT) unique expertise in developing treatment solutions for preterm infants, IBT is at an early...
2022-08-25 08:00
Infant Bacterial Therapeutics AB (publ) Interim Management Statement January 1-June 30, 2022
Message from the CEO Our IBP-9414 clinical phase III development program is progressing well. We have seen an overall acceleration of recruitment rates...
2022-06-30 17:00
Infant Bacterial Therapeutics AB appoints Maria Ekdahl as CFO
Press Release June 30, 2022 Infant Bacterial Therapeutics AB (publ) announced today that Maria Ekdahl has been appointed Chief Financial Officer (CFO)...
2022-05-04 18:00
Infant Bacterial Therapeutics AB (publ) Interim Management Statement, January 1 – March 31, 2022
Message from the CEO IBT's vision is to become an internationally leading company in the development of pharmaceuticals in the areas of premature infants...
2022-05-04 16:00
Annual General Meeting of Infant Bacterial Therapeutics
At the Annual General Meeting of Infant Bacterial Therapeutics AB (publ) on May 4, 2022, among other things, the following was resolved: About Infant Bacterial...
Shareholders of Infant Bacterial Therapeutics AB (publ) are summoned to the Annual General Meeting on Wednesday, May 4, 2022. In light of the coronavirus...
2022-03-31 08:00
Infant Bacterial Therapeutics publishes Annual Report for 2021
Press release March 31, 2022 Infant Bacterial Therapeutics AB (publ) publishes today the Annual Report for 2021. The report is available on IBT’s...
2022-02-04 20:00
Infant Bacterial Therapeutics AB (publ) Interim Management Statement, January 1 – December 31, 2021
Press release February 4, 2022 Message from the CEO IBT’s ongoing pivotal phase lll clinical trial aims to generate data to improve survival possibilities...